Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)

Vaccine

Volumn 32, Issue 1, 2013, Pages 124-130

  Bettinger, Julie A ^a   Scheifele, David W ^a   Halperin, Scott A ^b   Vaudry, Wendy ^c   Findlow, Jamie ^d   Borrow, Ray ^d   Medini, Duccio ^e   Tsang, Raymond ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

4CMenB coverage; Invasive meningococcal disease; Meningitis; Meningococcal Antigen Typing System; Serogroup B vaccines

Indexed keywords

4 COMPONENT MENINGOCOCCAL B VACCINE; ADHESIN; BINDING PROTEIN; FACTOR H BINDING PROTEIN; HEPARIN BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIA HEPARIN BINDING ANTIGEN; NEISSERIAL ADHESIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HLA TYPING; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; MENINGOCOCCAL SEROGROUP B; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

4CMENB COVERAGE; INVASIVE MENINGOCOCCAL DISEASE; MENINGITIS; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; SEROGROUP B VACCINES;

ANTIGENS, BACTERIAL; CANADA; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; POPULATION SURVEILLANCE; PREVALENCE;

EID: 84891912833     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.063     Document Type: Article

References (31)

1. Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009, 36:1-40.
2. Bettinger J.A., Scheifele D.W., Le Saux N., Halperin S.A., Vaudry W., Tsang R. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013, 32:e20-e25.
3. Edelman G.M. Cell adhesion molecules. Science 1983, 219:450-457.
4. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, 2:355-357.
5. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000, 3:445-450.
6. Feavers I.M., Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009, 27:B42-B50.
7. Feavers I.M., Pizza M. Choosing isolates for the evaluation of meningococcal protein vaccines. Expert Rev Vaccines 2009, 8:1461-1463.
8. Serruto D., Bottomley M.J., Ram S., Giuliani M.M., Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012, 30(Suppl. 2):B87-B97.
9. Gregory A. Biggest advance against meningitis in 30 years: new jab approved which could save thousands of lives 2013, Mirror, London. online ed.
10. Pillai S., Howell A., Alexander K., Bentley B.E., Jiang H.Q., Ambrose K., et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005, 23:2206-2209.
11. Caron F., du Chatelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11:455-463.
12. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
13. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines - an unfinished story. Lancet Infect Dis 2010, 10:112-124.
14. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362:1511-1520.
15. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
16. Zhou J., Lefebvre B., Deng S., Gilca R., Deceuninck G., Law D.K., et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012, 50:1545-1551.
17. Gilca R., Deceuninck G., Lefebvre B., Tsang R., Amini R., Gilca V., et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS ONE 2012, 7:1-9.
18. Scheifele D.W. IMPACT after 17 years: lessons learned about successful networking. Paediatr Child Health 2009, 14:33-35.
19. Bettinger J., Scheifele D., Le Saux N., Halperin S., Vaudry W., Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009, 28:220-224.
20. Le Saux N., Bettinger J.A., Wootton S., Halperin S.A., Vaudry W., Scheifele D.W., et al. Profile of serogroup Y meningococcal infections in Canada: implications for vaccine selection. For the members of the Canadian Immunization Monitoring Program, Active (IMPACT). Can J Infect Dis Med Microbiol 2009, 20:e130-e134.
21. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140-3145.
22. Jolley KA, Maiden MC. In: Oxford Uo, editor. Neisseria Multi Locus Sequence Typing website. Wellcome Trust and European Union; 2012-09-26.
23. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
24. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
25. Plikaytis B.D., Stella M., Boccadifuoco G., Detora L.M., Agnusdei M., Santini L., et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19:1609-1617.
26. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. PRedicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases 2013; in Press.
27. Ashton F.E., Caugant D.A. The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. Can J Microbiol 2001, 47:283-289.
28. Biolchi A., Lo Sapio M., Frosi G., Stella M., Brunelli B., Comanducci M., et al. Meningococcal Antigen Typing System (MATS) was a conservative estimate of killing when confirmed in a serum bactericidal assay using human complement (hSBA). 18th international pathogenic Neisseria conference, P276 2012, 427. University of Wurzburg, Wurzburg, Germany.
29. Fagnocchi L., Pigozzi E., Scarlato V., Delany I. In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J Bacteriol 2012, 194:460-474.
30. Litt D.J., Savino S., Beddek A., Comanducci M., Sandiford C., Stevens J., et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004, 190:1488-1497.
31. Snape M.D., Medini D., Halperin S.A., DeTora L., Drori J., Moxon E.R. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(Suppl. 2):B67-B72.